Efficacy Assays in Drug Discovery Using Zebrafish

Unlocking Therapeutic Potential with Zebrafish Models

Efficacy testing is one of the most decisive steps in the drug discovery pipeline. Before a compound advances toward clinical development, we must demonstrate that it produces the desired biological effect in a living system and does so with sufficient potency, specificity, and safety margins. Traditionally, rodent models have been the standard for these evaluations, but they are expensive, time-consuming, and often limited in scalability. Zebrafish (Danio rerio), on the other hand, have emerged as a powerful complementary model, bridging the gap between in vitro assays and mammalian studies while offering whole-organism insights that accelerate early-stage decision-making.

Why Zebrafish Are Ideal for Efficacy Assays

Due to their advantages, zebrafish efficacy assays are widely used in both academic and industry settings to identify promising candidates earlier and de-risk downstream development: 

• Genetic homology: Approximately 70% of human genes have at least one zebrafish ortholog, and about 82% of human disease-related genes are conserved. 
• Optical transparency: Their embryos are transparent, allowing direct observation of organ development, cellular interactions, and compound effects in real-time. 
• Whole-organism context: Unlike cell cultures, zebrafish provide a whole-organism context that captures systemic toxicity and efficacy, making results more predictive of human biology.
• Cost-efficient and scalable: Zebrafish require minimal space and resources compared to mammalian models. Their small size and social nature allow for compact, high-density housing, supporting large-scale research at a lower cost.
• High reproductive capacity: With spawning every 10 days and 200-300 eggs per spawning, zebrafish provide large sample sizes that strengthen statistical power.
• External fertilization and development: Eggs develop outside the mother, enabling easy administration of drugs (water incubation), straightforward gene editing, in vitro fertilization, and direct observation of early development. 
• Whole-organism studies in plate-based formats: Embryos and larvae fit into multi-well plates, combining the throughput of in vitro assays with the complexity of a living vertebrate.
• High-throughput screening: Their fecundity and small larval size make zebrafish ideal for testing large compound libraries in parallel.
• Ethical alignment: The zebrafish model reduces dependence on mammalian studies and aligns with the 3Rs principle. Under EU Directive 2010/63, embryos remain outside the scope of animal protection legislation until 5 dpf, providing an additional ethical advantage for early, high-throughput experimentation.

Applications in Therapeutic Areas

Zebrafish models have become indispensable tools across a broad range of therapeutic research areas.

Cancer Research

Zebrafish cancer models have evolved into powerful platforms for preclinical oncology research. Their genetic similarity to humans and transparent embryonic development allow real-time visualization of tumor growth, invasion, and metastasis in vivo. Because zebrafish larvae lack a fully developed adaptive immune system during early stages, human cancer cells can be xenografted without rejection, enabling the study of tumor behavior in a living organism. These xenograft models, combined with transgenic lines engineered to overexpress oncogenes or mimic spontaneous tumorigenesis, provide valuable systems to assess drug efficacy, monitor apoptotic responses, and evaluate tumor regression. We can also test drug combinations and optimize dosing regimens in days rather than weeks, significantly accelerating preclinical decision-making. 

Neurological Disorders

The zebrafish nervous system shares key structural and functional features with humans, including basic brain architecture, neurotransmitter system, and neuronal pathways, which makes it an excellent model for studying neurological diseases and their potential therapies. Behavioral assays can measure drug effects on locomotion, sensory processing, and seizure activity, supporting preclinical research into conditions such as epilepsy, Parkinson’s disease, and Alzheimer’s disease. Transgenic lines expressing human disease-associated genes offer additional opportunities to validate targets and test candidate therapeutics in vivo.

Ophthalmic Disorders

Traditional rodent models have significant limitations when it comes to studying visual disorders. Because mice are nocturnal, their retinas are predominantly rod-based with very few cones, and the cone photoreceptors they do have differ substantially from those in humans. Moreover, they often lack orthologous genes associated with human photoreceptor degeneration, making them less suitable for modeling retinal diseases. Zebrafish offer a more relevant and translationally valuable alternative. Their retinal architecture is highly conserved, and their cone-rich visual system, comprising four photoreceptor subtypes (UV, blue, green, and red), closely resembles that of humans. They also possess homologues of key genes involved in photoreceptor dysfunction, which enables to model disease mechanisms more accurately and test therapeutic interventions with higher predictive value.

Cardiovascular Disease 

Beyond regenerative medicine, zebrafish are increasingly used to evaluate drugs targeting cardiovascular conditions. Their rapid heart development and transparent embryos enable direct visualization of cardiac morphology, rhythm, and vascular dynamics, allowing us to quantify drug effects on heart rate, contractility, and vascular remodeling with high precision (Figure 1).

Figure 1. Cardiac kymographs displayed by ZeCardio^TM illustrate zebrafish heartbeat phenotypes after exposure to a negative control, a tachycardic, and a bradycardic compound.

Tissue Regeneration 

Zebrafish possess remarkable regenerative capacities, including the ability to repair cardiac tissue, spinal cord, retina, and even brain regions. This makes them invaluable for testing compounds aimed at promoting tissue regeneration and functional recovery. For example, zebrafish heart injury models allow researchers to screen molecules that enhance cardiomyocyte proliferation and improve post-injury cardiac performance, insights that can guide regenerative therapy development in humans.

How Efficacy Testing Works in Zebrafish

Efficacy assays in zebrafish can be broadly divided into three categories: morphological, pathway-based, and behavioral. Each provides complementary insights into how a compound interacts with the organism:

• Morphological assays assess visible changes in organ structure or dynamics, tissue growth, or developmental patterns following drug exposure. For example, angiogenesis assays quantify alterations in blood vessel formation, while cardiac assays measure changes in heart size, rhythm, or chamber structure.
• Pathway assays focus on molecular mechanisms, often using fluorescent reporter lines or transgenic models to visualize specific signaling cascades. This approach allows researchers to confirm that a compound engages its intended target in vivo and to map downstream effects across multiple tissues.
• Behavioral assays capture functional outcomes that emerge from systemic drug effects. These include measurements of locomotor activity, sensory response, learning and memory, and social interaction. Such assays are especially useful in neurological drug discovery, where subtle changes in behavior can indicate therapeutic efficacy or adverse effects.

Data from these assays are typically integrated into early decision-making workflows. Hits identified in zebrafish screens can undergo further optimization and validation in mammalian models, reducing the risk of late-stage failures and increasing the likelihood of clinical success. By bridging the gap between target discovery and preclinical development, zebrafish efficacy assays improve both the speed and quality of the drug discovery process.

Summary

Zebrafish models are revolutionizing efficacy assessment in drug discovery. By offering real-time, whole-organism insights across diverse therapeutic areas, zebrafish streamline the development of safe and effective therapies. Their scalability and versatility ensure that they remain a cornerstone of modern pharmaceutical research.

References

Cocchiaro P, Di Donato V, Rubbini D, Mastropasqua R, Allegretti M, Mantelli F, Aramini A, Brandolini L. Intravitreal Administration of rhNGF Enhances Regenerative Processes in a Zebrafish Model of Retinal Degeneration. Front Pharmacol. 2022 Mar 7;13:822359. doi: 10.3389/fphar.2022.822359.

Cornet C, Dyballa S, Terriente J, Di Giacomo V. ZeOncoTest: Refining and Automating the Zebrafish Xenograft Model for Drug Discovery in Cancer. Pharmaceuticals (Basel). 2019 Dec 24;13(1):1. doi: 10.3390/ph13010001.

Dyballa S, Miñana R, Rubio-Brotons M, Cornet C, Pederzani T, Escaramis G, Garcia-Serna R, Mestres J, Terriente J. Comparison of Zebrafish Larvae and hiPSC Cardiomyocytes for Predicting Drug-Induced Cardiotoxicity in Humans. Toxicol Sci. 2019 Oct 1;171(2):283-295. doi: 10.1093/toxsci/kfz165. 

Garbelli M, Neuhauss SCF. Color vision: Parsing spectral information for opponent color vision in the fish retina. Curr Biol. 2021 Dec 6;31(23):R1525-R1527. doi: 10.1016/j.cub.2021.10.016.

Locubiche S, Ordóñez V, Abad E, Scotto di Mase M, Di Donato V, De Santis F. A Zebrafish-Based Platform for High-Throughput Epilepsy Modeling and Drug Screening in F0. Int J Mol Sci. 2024 Mar 4;25(5):2991. doi: 10.3390/ijms25052991.

Patton EE, Zon LI, Langenau DM. Zebrafish disease models in drug discovery: from preclinical modelling to clinical trials. Nat Rev Drug Discov. 2021 Aug;20(8):611-628. doi: 10.1038/s41573-021-00210-8.

By Miriam Martínez

Miriam is a Human Biologist with a strong background in neuropharmacology and a passion for bridging science and innovation. After earning a master’s degree in the Pharmaceutical and Biotech Industry, she completed her PhD in Biomedicine at Pompeu Fabra University (Barcelona), where her research focused on the behavioral analysis of animal models for neurophenotypical characterization. Following her doctoral studies, Miriam transitioned into the healthcare marketing and communication sector, where she played a key role in developing impactful marketing strategies and educational campaigns for leading pharmaceutical brands. She now leverages her scientific expertise, strategic thinking, and creative communication skills in her current role at ZeClinics.